DOCSLIB.ORG

Toxicological Review of Benzo[A]Pyrene

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Toxicological Review of Benzo[A]Pyrene EPA/635/R-14/312a External Review Draft www.epa.gov/iris Toxicological Review of Benzo[a]pyrene (CASRN 50-32-8) In Support of Summary Information on the Integrated Risk Information System (IRIS) September 2014 NOTICE This document is an External Review draft. This information is distributed solely for the purpose of pre-dissemination peer review under applicable information quality guidelines. It has not been formally disseminated by EPA. It does not represent and should not be construed to represent any Agency determination or policy. It is being circulated for review of its technical accuracy and science policy implications. National Center for Environmental Assessment Office of Research and Development U.S. Environmental Protection Agency Washington, DC Toxicological Review of Benzo[a]pyrene DISCLAIMER This document is a preliminary draft for review purposes only. This information is distributed solely for the purpose of pre-dissemination peer review under applicable information quality guidelines. It has not been formally disseminated by EPA. It does not represent and should not be construed to represent any Agency determination or policy. Mention of trade names or commercial products does not constitute endorsement of recommendation for use. This document is a draft for review purposes only and does not constitute Agency policy. ii DRAFT—DO NOT CITE OR QUOTE Toxicological Review of Benzo[a]pyrene CONTENTS AUTHORS | CONTRIBUTORS | REVIEWERS ................................................................................................... ix PREFACE ....................................................................................................................................................... xii PREAMBLE TO IRIS TOXICOLOGICAL REVIEWS............................................................................................ xvi EXECUTIVE SUMMARY ............................................................................................................................ xxxiv LITERATURE SEARCH STRATEGY|STUDY SELECTION ................................................................................... xli 1. HAZARD IDENTIFICATION .................................................................................................................... 1-1 1.1. PRESENTATION AND SYNTHESIS OF EVIDENCE BY ORGAN/SYSTEM ............................................ 1-1 1.1.1. Developmental Toxicity ..................................................................................................... 1-1 1.1.2. Reproductive Toxicity ...................................................................................................... 1-22 1.1.3. Immunotoxicity ............................................................................................................... 1-37 1.1.4. Other Toxicity .................................................................................................................. 1-44 1.1.5. Carcinogenicity ................................................................................................................ 1-52 1.2. SUMMARY AND EVALUATION .................................................................................................... 1-81 1.2.1. Weight of Evidence for Effects Other than Cancer ......................................................... 1-81 1.2.2. Weight of Evidence for Carcinogenicity .......................................................................... 1-82 2. DOSE-RESPONSE ANALYSIS ................................................................................................................. 2-1 2.1. ORAL REFERENCE DOSE FOR EFFECTS OTHER THAN CANCER ...................................................... 2-1 2.1.1. Identification of Studies and Effects for Dose-Response Analysis .................................... 2-1 2.1.2. Methods of Analysis .......................................................................................................... 2-5 2.1.3. Derivation of Candidate Values ......................................................................................... 2-8 2.1.4. Derivation of Organ/System-Specific Reference Doses .................................................. 2-12 2.1.5. Selection of the Proposed Overall Reference Dose ........................................................ 2-14 2.1.6. Confidence Statement ..................................................................................................... 2-14 2.1.7. Previous IRIS Assessment: Reference Dose ..................................................................... 2-15 2.2. INHALATION REFERENCE CONCENTRATION FOR EFFECTS OTHER THAN CANCER ..................... 2-15 2.2.1. Identification of Studies and Effects for Dose-Response Analysis .................................. 2-15 2.2.2. Methods of Analysis ........................................................................................................ 2-17 2.2.3. Derivation of Candidate Values ....................................................................................... 2-19 2.2.4. Derivation of Organ/System-Specific Reference Concentrations ................................... 2-22 This document is a draft for review purposes only and does not constitute Agency policy. iii DRAFT—DO NOT CITE OR QUOTE Toxicological Review of Benzo[a]pyrene 2.2.5. Selection of the Proposed Reference Concentration ...................................................... 2-23 2.2.6. Confidence Statement ..................................................................................................... 2-23 2.2.7. Previous IRIS Assessment: Reference Concentration ...................................................... 2-24 2.2.8. Uncertainties in the Derivation of the RfD and RfC ........................................................ 2-24 2.3. ORAL SLOPE FACTOR FOR CANCER ............................................................................................. 2-25 2.3.1. Analysis of Carcinogenicity Data ..................................................................................... 2-25 2.3.2. Dose-Response Analysis—Adjustments and Extrapolation Methods ............................. 2-28 2.3.3. Derivation of the Oral Slope Factor ................................................................................. 2-28 2.3.4. Uncertainties in the Derivation of the Oral Slope Factor ................................................ 2-30 2.3.5. Previous IRIS Assessment: Oral Slope Factor .................................................................. 2-32 2.4. INHALATION UNIT RISK FOR CANCER ......................................................................................... 2-32 2.4.1. Analysis of Carcinogenicity Data ..................................................................................... 2-33 2.4.2. Dose-Response Analysis—Adjustments and Extrapolation Methods ............................. 2-34 2.4.3. Inhalation Unit Risk Derivation ........................................................................................ 2-35 2.4.4. Uncertainties in the Derivation of the Inhalation Unit Risk ............................................ 2-36 2.4.5. Previous IRIS Assessment: Inhalation Unit Risk ............................................................... 2-38 2.5. DERMAL SLOPE FACTOR FOR CANCER ........................................................................................ 2-39 2.5.1. Analysis of Carcinogenicity Data ..................................................................................... 2-39 2.5.2. Dose-Response Analysis—Adjustments and Extrapolation Methods ............................. 2-40 2.5.3. Derivation of the Dermal Slope Factor ............................................................................ 2-42 2.5.4. Dermal Slope Factor Cross-Species Scaling ..................................................................... 2-44 2.5.5. Uncertainties in the Derivation of the Dermal Slope Factor ........................................... 2-45 2.5.6. Previous IRIS Assessment: Dermal Slope Factor ............................................................. 2-47 2.6. APPLICATION OF AGE-DEPENDENT ADJUSTMENT FACTORS (ADAFS) ........................................ 2-47 REFERENCES ............................................................................................................................................... R-1 This document is a draft for review purposes only and does not constitute Agency policy. iv DRAFT—DO NOT CITE OR QUOTE Toxicological Review of Benzo[a]pyrene TABLES Table ES-1. Organ/system-specific RfDs and proposed overall RfD for benzo[a]pyrene ....................... xxxv Table ES-2. Organ/system-specific RfCs and proposed overall RfC for benzo[a]pyrene ...................... xxxvii Table LS-1. Summary of the search strategy employed for benzo[a]pyrene ............................................ xli Table 1-1. Evidence pertaining to developmental effects of benzo[a]pyrene in humans ........................ 1-4 Table 1-2. Evidence pertaining to developmental effects of benzo[a]pyrene in animals ........................ 1-5 Table 1-3. Evidence pertaining to the neurodevelopmental effects of benzo[a]pyrene from PAH mixtures ......................................................................................................................... 1-13 Table 1-4. Evidence pertaining to the neurodevelopmental effects of benzo[a]pyrene in animals ...... 1-15 Table 1-5. Evidence pertaining to the male reproductive toxicity of benzo[a]pyrene in adult
Load more

Recommended publications
  • Verrucous Carcinoma and Squamous Cell Papilloma of the Oral Cavity: Report of Two Cases and Review of Literature
    Published online: 2019-09-04 Case Report Verrucous carcinoma and squamous cell papilloma of the oral cavity: Report of two cases and review of literature Hilal Alan1, Serkan Agacayak2, Gulten Kavak2, Ayse Ozcan1 1Department of Oral and Maxillofacial Surgery, University of Inonu, Malatya, Turkiye, Correspondence: Dr. Hilal Alan 2Department of Oral and Maxillofacial Surgery, Email: [email protected] University of Dıcle, Diyarbakır, Turkiye ABSTRACT Verrucous carcinoma (VC) of oral cavity is a rare variant of well‑differentiated squamous cell carcinoma and squamous papilloma is a benign proliferation of the stratified squamous epithelium, which results in a papillary or verrucous exophytic mass. There is a certain clinical similarity between squamous cell papilloma and VC. We presented a report of two cases which are VC and squamous cell papilloma that are showed the same clinical appearance but different pathological appearance, with a review of the literature. Key words: Oral cavity, squamous cell papilloma, verrucous carcinoma INTRODUCTION that 15–51% of oral VCs are found in individuals without these habits.[11] Other etiologic factors include Oral verrucous carcinoma (VC), as defined immunosuppression, human papillomavirus (HPV), by Ackerman, is a rare, nonmetastasizing, and other viruses. The treatment of oral VC remains well‑differentiated variant of oral squamous cell controversial. Surgery, chemotherapy, radiotherapy, carcinoma (SCC).[1] Although VC has a slow and or a combination of procedures has been used in the continuous
    [Show full text]
  • Squamous Papilloma : a Case Report
    International Journal of Current Medical And Applied Sciences, vol.6. Issue 3, May: 2015. PP: 190-192. Squamous Papilloma : A Case Report Neha Desai*, Lata Kale**, Vishal Patil*** & Anand Swami* *Post Graduate Student, **Professor and HOD, Department of oral Medicine and Radiology, ***Post Graduate student, Department of Oral and Maxillofacial Surgery, C.S.M.S.S. , Dental College and hospital, Aurangabad,[MS],India. Corresponding Email ID: [email protected] Case Report Subject: Dental Sciences ----------------------------------------------------------------------------------------------------------------------------- --------------------- Abstract: case of squamous papilloma of buccal mucosa along Papillary and verruciform epithelial proliferations with a review of the literature. are quite common in the oral and para-oral region, representing at least 3% of biopsied oral lesions. Case Report: Many are thought to be induced by viral infection of A 37-year-old married male reported to the the epithelium. These exophytic proliferations may department of Oral Medicine of C.S.M.S.S Dental often shown tendency to undergo neoplastic changes. College and hospital Aurangabad with a chief The papilloma is a benign mucosal mass produced by complaint of pain in lower left back region of jaw due a strain of the papilloma virus, the virus which to partially erupted third molar. On general produces skin warts. However unlike warts examination a papillary growth was observed on left papilloma is not contagious, like a wart, and can be buccal mucosa (Figure 1). History regarding the removed by conservative surgery or laser growth revealed that it was first seen about six to destruction. Here we present you a case of benign eight months prior as a slow-growing non-tender squamous papilloma of left buccal mucosa.
    [Show full text]
  • Head and Neck Pathology (1317-1386)
    LABORATORY INVESTIGATION THE BASIC AND TRANSLATIONAL PATHOLOGY RESEARCH JOURNAL LI VOLUME 98 | SUPPLEMENT 1 | MARCH 2018 2018 ABSTRACTS HEAD AND NECK PATHOLOGY (1317-1386) 107TH ANNUAL MEETING GEARED TO LEARN Vancouver Convention Centre MARCH 17-23, 2018 Vancouver, BC, Canada PLATFORM & 2018 ABSTRACTS POSTER PRESENTATIONS EDUCATION COMMITTEE Jason L. Hornick, Chair Amy Chadburn Rhonda Yantiss, Chair, Abstract Review Board Ashley M. Cimino-Mathews and Assignment Committee James R. Cook Laura W. Lamps, Chair, CME Subcommittee Carol F. Farver Steven D. Billings, Chair, Interactive Microscopy Meera R. Hameed Shree G. Sharma, Chair, Informatics Subcommittee Michelle S. Hirsch Raja R. Seethala, Short Course Coordinator Anna Marie Mulligan Ilan Weinreb, Chair, Subcommittee for Rish Pai Unique Live Course Offerings Vinita Parkash David B. Kaminsky, Executive Vice President Anil Parwani (Ex-Officio) Deepa Patil Aleodor (Doru) Andea Lakshmi Priya Kunju Zubair Baloch John D. Reith Olca Basturk Raja R. Seethala Gregory R. Bean, Pathologist-in-Training Kwun Wah Wen, Pathologist-in-Training Daniel J. Brat ABSTRACT REVIEW BOARD Narasimhan Agaram Mamta Gupta David Meredith Souzan Sanati Christina Arnold Omar Habeeb Dylan Miller Sandro Santagata Dan Berney Marc Halushka Roberto Miranda Anjali Saqi Ritu Bhalla Krisztina Hanley Elizabeth Morgan Frank Schneider Parul Bhargava Douglas Hartman Juan-Miguel Mosquera Michael Seidman Justin Bishop Yael Heher Atis Muehlenbachs Shree Sharma Jennifer Black Walter Henricks Raouf Nakhleh Jeanne Shen Thomas Brenn John
    [Show full text]
  • The Efficacy of Imiquimod on Dysplastic Lesions of the Oral Mucosa: an Experimental Model
    ANTICANCER RESEARCH 30: 2891-2896 (2010) The Efficacy of Imiquimod on Dysplastic Lesions of the Oral Mucosa: An Experimental Model VASILIKI GKOULIONI1, ANNA ELEFTHERIADOU2, IOANNIS YIOTAKIS3, ELIZA FEREKIDOU3, ARISTIDIS CHRISOVERGIS3, ANDREAS CH. LAZARIS4 and DIMITRIOS KANDILOROS3 1Center of Experimental Surgery, Foundation of Biomedical Research, Academy of Athens, Athens, Greece 2Department of Otolaryngology, General Hospital of Rethymnon, Crete, Greece; 3Department of Otolaryngology, Hippokration Hospital, University of Athens, Athens, Greece; 4Department of Pathology, University of Athens, Greece Abstract. Aim: To study the potent efficacy of the The most common precancerous lesion of the oral mucosa immunomodulatory agent imiquimod when applied on is leukoplakia, which in fact is a clinical term only. “Oral dysplastic lesions of the oral mucosa. Materials and leukoplakia is a predominant white lesion of the oral mucosa Methods: Carcinogen (DMBA) was applied to the mucosa of that cannot be characterized as any other definable lesion. the left buccal pouch of 26 male Wistar rats for 8 weeks, Some oral leukoplakias will transform into cancer” (1). until dysplastic lesions were observed and histologically Histological examination of leukoplakia is always necessary, diagnosed. At the second phase of the experiment, 5% in order to determine the exact grade of histological lesion, if imiquimod cream was applied to these dysplastic lesions for present. Hence a white lesion of the oral mucosa can either 16 weeks. Biopsies were taken before and after treatment. be dysplastic or non-dysplastic. This is why the term Results: The histological effect of imiquimod was the leukoplakia remains strictly a clinical term only, and after a regression of mild dysplasia to hyperplasia for all the biopsy is performed, the term leukoplakia is replaced by the samples.
    [Show full text]
  • “Leukoplakia- Potentially Malignant Disorder of Oral Cavity -A Review”
    DOI: 10.26717/BJSTR.2018.04.001126 Neha Aggarwal. Biomed J Sci & Tech Res ISSN: 2574-1241 Review Article Open Access “Leukoplakia- Potentially Malignant Disorder of Oral Cavity -a Review” Neha Aggarwal*1 and Sumit Bhateja2 1Department of Oral Medicine & Radiology, Manav Rachna Dental College & Hospital, Faridabad, India 2Reader Dept of Oral Medicine and Radiology, Manav Rachna Dental College, India Received: May 18, 2018; Published: May 29, 2018 *Corresponding author: Neha Aggarwal, Senior Lecturer (MDS), Department of Oral Medicine & Radiology, Manav Rachna Dental College & Hospital, Faridabad, India Abstract The term Leukoplakia simply means a “white patch”, and it has been used in a sense to describe any white lesion in the mouth. This lesions. Some investigators tried, although unsuccessfully, to restrict this term only to those white lesions that histologically indicated epithelial non-specific usage led to confusion among physician, surgeons and researchers who attributed a precancerous nature to many innocuous dysplasia. Since the mid-1960s there has been a considerable understanding and clarification in the concept of leukoplakia, and now leukoplakia isKeywords: recognized Leukoplakia; as a specific Potentially entity. malignant disorder Introduction increased risk for cancer. Leukoplakia is a clinical term and the le Leukoplakia is a greek word- Leucos means white and Plakia- - (acanthosis) and may or may not demonstrate epithelial dysplasia. ry by the Hungarian dermatologist, Schwimmer in 1877 [1,2]. WHO sion has no specific histology. It may show atrophy or hyperplasia means patch. It was first coined in the second half of the 19th centu It has a variable behavioural pattern but with an assessable tenden- (1978) [3]- A white patch or plaque that cannot be characterized cy to malignant transformation.
    [Show full text]
  • HPV-Associated Benign Squamous Cell Papillomas in the Upper Aero-Digestive Tract and Their Malignant Potential
    viruses Review HPV-Associated Benign Squamous Cell Papillomas in the Upper Aero-Digestive Tract and Their Malignant Potential Stina Syrjänen 1,2,* and Kari Syrjänen 3 1 Department of Oral Pathology and Oral Radiology, Institute of Dentistry, Faculty of Medicine, University of Turku, 20520 Turku, Finland 2 Department of Pathology, Turku University Hospital, 20521 Turku, Finland 3 Department of Clinical Research, Biohit Oyj, 00880 Helsinki, Finland; kasyrja@sci.fi * Correspondence: stina.syrjanen@utu.fi Abstract: Squamous cell papilloma (SCP) in the upper aero-digestive tract is a rare disease entity with bimodal age presentation both at childhood and in adults. It originates from stratified squamous and/or respiratory epithelium. Traditionally, SCPs have been linked to chemical or mechanical irritation but, since the 1980s, they have also been associated with human papillomavirus (HPV) infection. Approximately 30% of the head and neck SCPs are associated with HPV infection, with this association being highest for laryngeal papillomas (76–94%), followed by oral (27–48%), sinonasal (25–40%), and oropharyngeal papillomas (6–7%). There is, however, a wide variation in HPV prevalence, the highest being in esophageal SCPs (11–57%). HPV6 and HPV11 are the two main HPV genotypes present, but these are also high-risk HPVs as they are infrequently detected. Some 20% of the oral and oropharyngeal papillomas also contain cutaneous HPV genotypes. Despite their Citation: Syrjänen, S.; Syrjänen, K. benign morphology, some SCPs tend to recur and even undergo malignant transformation. The HPV-Associated Benign Squamous highest malignant potential is associated with sinonasal inverted papillomas (7–11%). This review Cell Papillomas in the Upper discusses the evidence regarding HPV etiology of benign SCPs in the upper aero-digestive tract Aero-Digestive Tract and Their and their HPV-related malignant transformation.
    [Show full text]
  • Review Article Oral Leukoplakia As It Relates to HPV Infection: a Review
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Crossref Hindawi Publishing Corporation International Journal of Dentistry Volume 2012, Article ID 540561, 7 pages doi:10.1155/2012/540561 Review Article Oral Leukoplakia as It Relates to HPV Infection: A Review L. Feller and J. Lemmer Department of Periodontology and Oral Medicine, University of Limpopo, Medunsa Campus, Medunsa, South Africa Correspondence should be addressed to L. Feller, [email protected] Received 13 July 2011; Revised 2 September 2011; Accepted 19 December 2011 Academic Editor: Neil S. Norton Copyright © 2012 L. Feller and J. Lemmer. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Leukoplakia is the most common potentially malignant lesion of the oral cavity and can be categorised according to its clinical appearance as homogeneous or nonhomogenous. Tobacco and areca nut use, either alone or in combination are the most common risk factors for oral leukoplakia, but some oral leukoplakias are idiopathic. Some leukoplakias arise within fields of precancerized oral epithelium in which the keratinocytes may be at different stages of cytogenetic transformation. Leukoplakias may unpredictably regress, may remain stable, or may progress to carcinoma. There is a greater risk of carcinomatous transformation of idiopathic leukoplakia, of non-homogenous leukoplakia, of leukoplakia affecting the floor of the mouth; the ventrolateral surface of the tongue and the maxillary retromolar and adjoining soft palate (collectively called high-risk sites), of leukoplakia with high-grade epithelial dysplasia, and of leukoplakia in which the keratinocytes carry cytogenetic alterations associated with carcinomatous transformation.
    [Show full text]
  • Non–Plaque-Induced Gingival Diseases
    Received: 9 March 2017 Revised: 4 September 2017 Accepted: 13 September 2017 DOI: 10.1002/JPER.17-0163 2017 WORLD WORKSHOP Non–plaque-induced gingival diseases Palle Holmstrup1 Jacqueline Plemons2 Joerg Meyle3 1 Section of Periodontology, Department of Abstract Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, While plaque-induced gingivitis is one of the most common human inflammatory Copenhagen, Denmark diseases, several non–plaque-induced gingival diseases are less common but often 2Department of Periodontics, Texas A&M of major significance for patients. The non–plaque-induced gingival lesions are University College of Dentistry, Dallas, TX, USA often manifestations of systemic conditions, but they may also represent pathologic 3Department of Periodontology, University changes limited to gingival tissues. A classification is proposed, based on the etiol- of Giessen, Giessen, Germany ogy of the lesions and includes: Genetic/Developmental disorders; Specific infections; Correspondence Inflammatory and immune conditions and lesions; Reactive processes; Neoplasms; Prof. Palle Holmstrup, Section of Periodon- Endocrine, Nutritional and metabolic diseases; Traumatic lesions; and Gingival tology, Department of Odontology, Faculty of Health and Medical Sciences, University pigmentation. of Copenhagen, 20 Noerre Allé, DK-2200 Copenhagen, Denmark. KEYWORDS Email: [email protected] classification, diagnosis oral, epulis, gingiva, gingival diseases, immunological, inflammation, mouth The proceedings of the workshop were mucosa,
    [Show full text]
  • SNODENT (Systemized Nomenclature of Dentistry)
    ANSI/ADA Standard No. 2000.2 Approved by ANSI: December 3, 2018 American National Standard/ American Dental Association Standard No. 2000.2 (2018 Revision) SNODENT (Systemized Nomenclature of Dentistry) 2018 Copyright © 2018 American Dental Association. All rights reserved. Any form of reproduction is strictly prohibited without prior written permission. ADA Standard No. 2000.2 - 2018 AMERICAN NATIONAL STANDARD/AMERICAN DENTAL ASSOCIATION STANDARD NO. 2000.2 FOR SNODENT (SYSTEMIZED NOMENCLATURE OF DENTISTRY) FOREWORD (This Foreword does not form a part of ANSI/ADA Standard No. 2000.2 for SNODENT (Systemized Nomenclature of Dentistry). The ADA SNODENT Canvass Committee has approved ANSI/ADA Standard No. 2000.2 for SNODENT (Systemized Nomenclature of Dentistry). The Committee has representation from all interests in the United States in the development of a standardized clinical terminology for dentistry. The Committee has adopted the standard, showing professional recognition of its usefulness in dentistry, and has forwarded it to the American National Standards Institute with a recommendation that it be approved as an American National Standard. The American National Standards Institute granted approval of ADA Standard No. 2000.2 as an American National Standard on December 3, 2018. A standard electronic health record (EHR) and interoperable national health information infrastructure require the use of uniform health information standards, including a common clinical language. Data must be collected and maintained in a standardized format, using uniform definitions, in order to link data within an EHR system or share health information among systems. The lack of standards has been a key barrier to electronic connectivity in healthcare. Together, standard clinical terminologies and classifications represent a common medical language, allowing clinical data to be effectively utilized and shared among EHR systems.
    [Show full text]
  • Sialadenoma Papilliferum
    Chen et al. Diagnostic Pathology (2021) 16:22 https://doi.org/10.1186/s13000-021-01084-5 RESEARCH Open Access Sialadenoma papilliferum: clinicopathologic, Immunohistochemical, molecular analyses of new five cases and review of the literature Shuai Chen1,2, Jie Peng2,3, Chuantao Yuan2, Lin Sun1, Renya Zhang2* and Yan Sun1* Abstract Background: Sialadenoma papilliferum (SP) is an extremely rare benign neoplasm of salivary glands. To explore and define the clinicopathological features of SP, we retrospectively analyzed 89 cases previously reported and five new cases. Methods: The clinical features, histopathology, immunohistochemistry and molecular analysis of our cases were further performed and the related literatures were reviewed and analyzed. Results: Combining 89 cases from the literature with our cases, the hard palate was the most common locations for SP. However, two of our cases were rarely located in the esophageal mucosa. Among all cases, the male gender was more affected, with the average age and median age of 61.8 and 62 years, respectively. Conventional histomorphologically, SP was characterized by complex papillary structures with a biphasic growth pattern of exophytic squamous component and endophytic glandular component. The glandular structures were lined by a double layer of epithelium composed of flattened or cuboidal basal cells and a cuboidal or columnar luminal cells formed papillary infoldings into the ductal lumina. Immunohistochemically, the luminal epithelial configurations showed strong expression of CK7 along
    [Show full text]
  • Update on Diagnosis and Management of Conjunctival Papilloma Despoina Theotoka1†, Melina I
    Theotoka et al. Eye and Vision (2019) 6:18 https://doi.org/10.1186/s40662-019-0142-5 REVIEW Open Access Update on Diagnosis and Management of Conjunctival Papilloma Despoina Theotoka1†, Melina I. Morkin1†, Anat Galor1,2 and Carol L. Karp1* Abstract Conjunctival papilloma is an acquired benign squamous cell tumor that can present at any age, but most frequently in the third and fourth decades of life. Papillomas have been associated with human papilloma virus (HPV) infection, usually types 6 and 11. Although histopathological diagnosis remains the gold standard, the advent of newer non-invasive imaging modalities such as optical coherence tomography (OCT) is transforming the way we diagnose and treat ocular surface tumors, including conjunctival papilloma. Management of these lesions can prove a challenge to the treating physician since not all lesions respond to medical and/or surgical therapy and in fact may worsen after surgical manipulation. In this review, the epidemiology, pathophysiology, clinical characteristics, and diagnosis of conjunctival papilloma including the use of OCT are discussed. Indications, efficacy, and side effects of currently available management options are also reviewed to guide the selection of the best treatment approach. Keywords: Conjunctival papilloma, Squamous cell papilloma, Optical coherence tomography, Treatment, Interferon, Mitomycin, Surgery, Cryotherapy, Human papilloma virus Background Management of conjunctival papilloma is diverse and The first reported case of conjunctival papilloma both medical and surgical approaches have been de- dates back to 1883, when Critchett and Juler de- scribed. The course of papillomas can be complicated by scribed a small reddish mass near the inner canthus multiple recurrences, especially in the pediatric popula- of a 14-year-old girl presenting with discomfort and tion [3].
    [Show full text]
  • Its Unique Etiology and Association with Human Papilloma Virus
    https://www.scientificarchives.com/journal/journal-of-cancer-immunology Journal of Cancer Immunology Commentary Verrucous Carcinoma of the Esophagus: Its Unique Etiology and Association with Human Papilloma Virus Satoshi Tabuchi1, Kazuo Koyanagi2*, Soji Ozawa2, Shigeyuki Kawachi1 1Department of Digestive and Transplantation Surgery, Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, 193- 0998, Japan 2Department of Gastroenterological Surgery, Tokai University School of Medicine, Isehara, Kanagawa, 259-1193, Japan *Correspondence should be addressed to Kazuo Koyanagi; [email protected] Received date: May 02, 2020, Accepted date: May 14, 2020 Copyright: © 2020 Tabuchi S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Verrucous carcinoma of the esophagus (VCE) is a rare variant of esophageal squamous cell carcinoma. Most cases of VCE presents as an exophytic, slow-growing mass with a superficial growth pattern. Even when VCE exhibits a characteristic pattern during an endoscopic examination, it is very difficult to make a definitive diagnosis of VCE preoperatively, because biopsy specimens are only characterized by nonspecific acanthosis and hyperkeratosis or parakeratosis associated with inflammation. As well as the characteristics of VCE, the etiology of the disease is even unique. VCE is typically associated with chronic mucosal irritation such as reflux esophagitis, achalasia, and lye ingestion that has resulted in esophageal inflammation or a long-term local disease process in addition to the classic risk factors of nicotine and alcohol consumption. Recent studies had indicated that human papilloma virus (HPV) infection might be associated with VCE.
    [Show full text]